라미부딘 내성 만성 B형간염 환자에서 아데포비어 투여에 따른 내성 바이러스 출현 및 초기 바이러스반응에 미치는 인자 = Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients

참고문헌 (Reference)

1 Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B" 44 : 283-290, 2006

2 Ryu SH, "Resistance to adefovir in patients with chronic hepatitis B" 12 : 485-492, 2006

3 Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil" 55 : 1488-1495, 2006

4 Lee JH, "Primary adefovir resistance mutations in patients with YMDD mutation and resistance to lamivudine: the incidence and clinical course [Abstract]" 44 (44): 174-, 2006

5 Lai CL, "Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B" 36 : 687-696, 2003

6 Lok ASF, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003

7 Hadziyannis SJ, "Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg negative chronic hepatitis B: result after 5 years of therapy [Abstract]" 42 (42): 754A-, 2005

8 Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48weeks of adefovir dipivoxil monotherapy" 43 : 1385-1391, 2006

9 Locarnini S, "Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B [Abstract]" 42 (42): 36A-, 2005

10 Chang TT, "Hepatitis B virus with primary resistance to adefovir" 355 : 322-323, 2006

11 Yuen MF, "Factors associated with hepatitis B virus DNA breakthough in patients receiving prolonged lamivudine therapy" 34 : 785-791, 2001

12 Kim DY, "Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection" 27 : 47-53, 2007

13 Hong SP, "Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments" 40 : 837-844, 2004

14 van Bömmel F, "Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection" 40 : 1421-1425, 2004

15 Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B" 348 : 800-807, 2003

16 Marcellin P, "Adefovir dipivoxil for the treatment of Hepatitis B e antigen-positive chronic hepatitis B" 348 : 808-816, 2003

17 Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine- resistant chronic hepatitis B" 126 : 91-101, 2004

18 Perrillo R, "Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus" 126 : 81-90, 2004

19 Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine- resistant HBeAg-negative chronic hepatitis B" 45 : 307-313, 2007

20 Lok ASF, "AASLD Practice Guidelines: chronic hepatitis B" 45 : 507-539, 2007

21 Zeng M, "A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B" 44 : 108-116, 2006